|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
SULFAMETHOXAZOLE AND TRIMETHOPRIM
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Shigellosis |
|
Bronchitis, chronic, acute exacerbation |
|
Diarrhea, infectious |
|
Infection, ear, middle |
|
Infection, lower respiratory tract |
|
Infection, urinary tract |
|
Pneumonia, pneumocystis carinii |
| |
|
|
SIDE EFFECTS:
|
|
Hypersensitivity |
|
photosensitivity |
|
Blood dyscrasias |
|
cholestatic hepatitis |
|
pancreatitis |
|
Stevens-Johnson syndrome |
|
toxic epidermal necrolysis |
|
Aseptic meningitis |
|
central nervous system (CNS) toxicity |
|
Clostridium difficile colitis |
|
crystalluria or hematuria |
|
goiter or thyroid function disturbance |
|
interstitial nephritis or tubular necrosis |
|
methemoglobinemia |
|
rhabdomyolysis |
|
thrombophlebitis |
|
CNS effects |
|
gastrointestinal disturbances |
|
glossitis or stomatitis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Blood dyscrasias |
|
>> Megaloblastic anemia due to folate deficiency |
|
>> Glucose-6-phosphate dehydrogenase deficiency |
|
>> Hepatic function impairment |
|
>> Porphyria |
|
>> Renal function impairment |
|
|
ADULT DOSE:
|
|
Antibacterial (systemic)-
Intravenous infusion, 10 to 12.5 mg of sulfamethoxazole and 2 to 2.5 mg of trimethoprim per kg of body weight every six hours; 13.3 to 16.7 mg of sulfamethoxazole and 2.7 to 3.3 mg of trimethoprim per kg of body weight every eight hours; or 20 to 25 mg of sulfamethoxazole and 4 to 5 mg of trimethoprim per kg of body weight every twelve hours.
Antiprotozoal-
Pneumocystis carinii pneumonia: Intravenous infusion, 18.75 to 25 mg of sulfamethoxazole and 3.75 to 5 mg of trimethoprim per kg of body weight every six hours; or 25 to 33.3 mg of sulfamethoxazole and 5.0 to 6.7 mg of trimethoprim per kg of body weight every eight hours for fourteen days. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Infants up to 2 months of age-Use is not recommended since sulfonamides may cause kernicterus in neonates.
Infants 2 months of age and over-See Usual adult and adolescent dose. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|